Cairn Surgical this week announced it closed a $4.5 million Series A2 financing round for its Breast Cancer Locator System.

Lebanon, N.H.–based Cairn Surgical earmarked the funds to complete the currently enrolling U.S. pivotal trial of the Breast Cancer Locator (BCL) System and implement a limited commercial launch in some European markets. Morningside Ventures led the financing round.

“We are delighted to have the continued support of Morningside Ventures, who believes in our vision of improving both outcomes for breast cancer patients and the healthcare economics of breast cancer surgery,” CEO David Danielsen said in a news release. “By giving breast cancer surgeons detailed and critical information that they don’t have today, we intend to transform the surgical experience and through that, improve the patient experience, reducing the need for reexcision surgery.”

The current standard of care for breast-conserving surgery doesn’t remove the entire tumor about 20% of the time, Cairn Surgical said. The company said that occurs primarily because current breast tumor localization techniques do not provide the information needed to have precise removal of the entire tumor.

Cairn designed the BCL system to improve the accuracy of breast-conserving surgery by providing the surgeon with more critical information about the tumor, including size, shape, and precise location.

“Cairn Surgical has been – and continues to be – a key medtech investment for us,” said Mick Sawka, investment advisor with Morningside Ventures. “The company’s innovative image-derived guidance solution for breast cancer lumpectomy is showing great promise and progress, and has shown outstanding clinical results in its European clinical trial. We are excited about its potential to significantly improve patient care, as well as reduce costs to the healthcare system.”